These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29616864)

  • 21. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
    Lübbert M; Grishina O; Schmoor C; Schlenk RF; Jost E; Crysandt M; Heuser M; Thol F; Salih HR; Schittenhelm MM; Germing U; Kuendgen A; Götze KS; Lindemann HW; Müller-Tidow C; Heil G; Scholl S; Bug G; Schwaenen C; Giagounidis A; Neubauer A; Krauter J; Brugger W; De Wit M; Wäsch R; Becker H; May AM; Duyster J; Döhner K; Ganser A; Hackanson B; Döhner H;
    J Clin Oncol; 2020 Jan; 38(3):257-270. PubMed ID: 31794324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group (E1993).
    Dutcher JP; Lee S; Gallagher RE; Makary AZ; Hines JD; Londer H; Farnen JP; Bennett JM; Paietta E; Rowe JM; Goloubeva O; Wiernik PH;
    Leuk Lymphoma; 2005 Mar; 46(3):377-85. PubMed ID: 15621827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG).
    Asou N; Adachi K; Tamura J; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Sakamaki H; Tsubaki K; Saito K; Ohno R
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S30-5. PubMed ID: 9272131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.
    Schlenk RF; Fröhling S; Hartmann F; Fischer JT; Glasmacher A; del Valle F; Grimminger W; Götze K; Waterhouse C; Schoch R; Pralle H; Mergenthaler HG; Hensel M; Koller E; Kirchen H; Preiss J; Salwender H; Biedermann HG; Kremers S; Griesinger F; Benner A; Addamo B; Döhner K; Haas R; Döhner H;
    Leukemia; 2004 Nov; 18(11):1798-803. PubMed ID: 15385923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the relationship between Scl transcription factor complex protein expression patterns and the effects of LiCl on ATRA-induced differentiation in blast cells from patients with acute myeloid leukemia.
    Rice AM; Holtz KM; Karp J; Rollins S; Sartorelli AC
    Leuk Res; 2004 Nov; 28(11):1227-37. PubMed ID: 15380350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of all-trans-retinoic acid alone or in combination with chemotherapy in newly diagnosed acute promyelocytic leukaemia.
    Colović MD; Janković GM; Elezović I; Vidović A; Bila JS; Novak A; Babić D
    Med Oncol; 1997 Jun; 14(2):65-72. PubMed ID: 9330265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
    Sacchi S; Kantarjian HM; Freireich EJ; O'Brien S; Cortes J; Rios MB; Kornblau S; Giles FJ; Koller C; Gajewski J; Talpaz M
    Leuk Lymphoma; 1999 Nov; 35(5-6):483-9. PubMed ID: 10609785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy.
    Wu W; Lin Y; Xiang L; Dong W; Hua X; Ling Y; Li H; Yan F; Xie X; Gu W
    Ann Hematol; 2016 Jun; 95(7):1051-7. PubMed ID: 27116384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.
    Reikvam H; Hovland R; Forthun RB; Erdal S; Gjertsen BT; Fredly H; Bruserud Ø
    BMC Cancer; 2017 Sep; 17(1):630. PubMed ID: 28877686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autophagy contributes to dasatinib-induced myeloid differentiation of human acute myeloid leukemia cells.
    Xie N; Zhong L; Liu L; Fang Y; Qi X; Cao J; Yang B; He Q; Ying M
    Biochem Pharmacol; 2014 May; 89(1):74-85. PubMed ID: 24607273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.
    Kato S; Jardim DL; Johnson FM; Subbiah V; Piha-Paul S; Tsimberidou AM; Falchook GS; Karp D; Zinner R; Wheler J; Janku F; Fu S; Lim J; Bean S; Nguyen L; Urban S; Browne E; Meric-Bernstam F; Hong DS
    Invest New Drugs; 2018 Jun; 36(3):416-423. PubMed ID: 29047029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid.
    Yu KH; Weng LJ; Fu S; Piantadosi S; Gore SD
    Leukemia; 1999 Aug; 13(8):1258-65. PubMed ID: 10450755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
    Ocana A; Gil-Martin M; Antolín S; Atienza M; Montaño Á; Ribelles N; Urruticoechea A; Falcón A; Pernas S; Orlando J; Montero JC; Escudero MJ; Benito S; Caballero R; Carrasco E; Rojo F; Pandiella A; Ruiz-Borrego M
    Breast Cancer Res Treat; 2019 Apr; 174(3):693-701. PubMed ID: 30607629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.
    Grishina O; Schmoor C; Döhner K; Hackanson B; Lubrich B; May AM; Cieslik C; Müller MJ; Lübbert M
    BMC Cancer; 2015 May; 15():430. PubMed ID: 26008690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17).
    Bullinger L; Schlenk RF; Götz M; Botzenhardt U; Hofmann S; Russ AC; Babiak A; Zhang L; Schneider V; Döhner K; Schmitt M; Döhner H; Greiner J
    Clin Cancer Res; 2013 May; 19(9):2562-71. PubMed ID: 23444226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation.
    van Gils N; Verhagen HJMP; Smit L
    Exp Hematol; 2017 Aug; 52():12-23. PubMed ID: 28456748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triple combination of retinoic acid plus actinomycin D plus dimethylformamide induces differentiation of human acute myeloid leukaemic blasts in primary culture.
    Hassan HT; Rees J
    Cancer Chemother Pharmacol; 1990; 26(1):26-30. PubMed ID: 2322987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
    Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F
    J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.